Hematology

Filter

beta catenin degradation

Targeting Beta Catenin Degradation in B Cell Leukaemia

February 2026

New findings reveal that B cell acute lymphoblastic leukaemia depends on intact beta catenin degradation, highlighting glycogen synthase kinase 3 beta inhibition as a potential therapeutic strategy.

Gene-Editing Therapy for Sickle Cell Disease Approved by NHS

The NHS has approved exa-cel, a revolutionary gene-editing therapy for sickle cell disease, offering hope for a cure.

Shared Care Model for Hematopoietic Cell Transplantation Shows Promise

Shared care after HCT improves quality of life at day 100 without affecting survival, offering a viable post-transplant model.

Key Metabolic Vulnerability in Multiple Myeloma Treatment

New research identifies VLCFA metabolism as a target to boost multiple myeloma treatment efficacy and combat drug resistance.

Molecular Dynamics Behind Different Tumour Rejection Kinetics in CAR-T Cell Therapy

A recent study has uncovered key insights into the differing tumour rejection behaviours of chimeric antigen receptor T cells (CAR-T) targeting CD19…

Low Lymphocyte Count Linked to Poorer Survival in Multiple Myeloma

Low lymphocyte count at diagnosis and during treatment is associated with poorer survival in multiple myeloma patients.

Impact of TP53 Alterations on Myelodysplastic Prognosis

TP53 alterations impact relapse and disease-free survival in MDS patients undergoing haploidentical haematopoietic stem cell transplantation.

Brain Age Linked to Cognitive Impairment in Sickle Cell Anaemia and Economic Deprivation

A recent study shows brain age modelling can help understand cognitive impairments in adults with sickle cell anemia and economic deprivation.

Persistent DNA Lesions Contribute to Mutations Over Time

A study reveals DNA lesions that persist in stem cells, contributing to mutations, with implications for blood cancers.

Loading posts...

« Previous 1 … 15 16 17 18 19 … 44 Next »